Herbal agents and combination therapies, such as those containing β-carotene, isotretinoin, IFN-α 2a, and vitamin E, have shown encouraging results, although the long-term benefits remain uncertain...While chemopreventive strategies offer potential, their clinical application remains limited by inconsistent outcomes and adverse effects. Advancing this field requires the development of targeted therapies, personalised approaches based on molecular profiling, and innovative delivery systems like nanocarriers to improve therapeutic efficacy and safety.

P=N/A, N=200, Active, not recruiting, Bausch Health Americas, Inc. | Recruiting --> Active, not recruiting

P3, N=150, Recruiting, Quetzal Therapeutics

P2, N=100, Not yet recruiting, University of Nebraska

P2, N=40, Not yet recruiting, Assiut University

P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2025 --> Jun 2029

P1, N=18, Active, not recruiting, Dwight Owen | Trial completion date: Jan 2026 --> Dec 2026

P=N/A, N=40, Completed, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushuhu Hospital); The Fourth Affiliated Hospital of Soochow University (Suzhou Dushuhu H | Not yet recruiting --> Completed

We developed a biofunctional hybrid scaffold (PMEAR/MM/uEV) combining a porous poly(lactic-co-glycolic acid)-porcine extracellular matrix, ricinoleic acid-modified magnesium hydroxide, metanephric mesenchyme-like cells, and ureteric bud-derived extracellular vesicles, with resveratrol and adapalene to confer antioxidant and pro-regenerative properties...mRNA sequencing revealed activation of angiogenesis, extracellular matrix remodeling, oxidative defense, and immune modulation, with Kyoto Encyclopedia of Genes and Genomes enrichment in tumor necrosis factor and interleukin-17 signaling and nuclear factor kappa B-associated pathways. These findings establish PMEAR/MM/uEV as an effective, multimodal platform for kidney regeneration.

P=N/A, N=64, Completed, University of Medicine and Pharmacy at Ho Chi Minh City

P=N/A, N=102, Active, not recruiting, Pierre Fabre Dermo Cosmetique

In this single-center retrospective study, children with a median age 5.1 years (range, 2.0-11.1 years) with R/R HR-NB who were treated with >5 cycles of dinutuximab beta (10 mg/m2/day for 10-days per 35-day cycle), granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin, plus chemotherapy, were included. No immune-related deaths occurred. Overall, cycles beyond the standard 5 cycles of dinutuximab beta with chemoimmunotherapy were effective and tolerable in pediatric patients with R/R HR-NB, demonstrating improved response and survival outcomes.